Effects of Ketamine in the Acute Phase of Suicidal Ideation

Ketamine

Brief Summary

The primary objective of this study is to assess the efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS hetero questionnaire, in patients hospitalized for suicide risk.

Intervention / Treatment

  • Baseline evaluation (OTHER)
    Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
  • 1st perfusion of ketamine (DRUG)
    A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
  • 1st perfusion of saline (DRUG)
    A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
  • Follow-up between perfusions (OTHER)
    Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
  • 2nd perfusion of ketamine (DRUG)
    A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
  • 2nd perfusion of saline (DRUG)
    A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)

Condition or Disease

  • Suicidal Ideation

Phase

  • Phase 3

    • Study Design

    Study type: INTERVENTIONAL
    Status: Completed
    Study results: No Results Available
    Age: 18 Years and older   (Adult, Older Adult)
    Enrollment: 156 (ACTUAL)
    Funded by: Other
    Allocation: Randomized
    Primary Purpose: Treatment

    Masking

    DOUBLE:
    • Participant
    • Investigator

    Clinical Trial Dates

    Start date: Apr 01, 2015 ACTUAL
    Primary Completion: Mar 12, 2019 ACTUAL
    Completion Date: Mar 26, 2019 ACTUAL
    Study First Posted: Nov 24, 2014 ESTIMATED
    Results First Posted: Aug 31, 2020
    Last Updated: May 27, 2019

    Sponsors / Collaborators

    Lead Sponsor: Centre Hospitalier Universitaire de Nīmes
    Lead sponsor is responsible party
    Responsible Party: N/A

    Location

    Paris, Île-de-France, France
    Lille, Hauts-de-France, France
    Nîmes, Occitanie, France
    Saint-Cyr-sur-Loire, Centre, France
    Clermont-Ferrand, Auvergne-Rhône-Alpes, France
    Montpellier, Occitanie, France

    The secondary objectives of this study are to assess:

    A. The maintenance of medium-term effectiveness of ketamine on the resolution of suicidal ideation

    B. The evolution of the full spectrum of suicidality under ketamine compared to placebo

    C. The evolution of psychic and physical pain scores under ketamine compared to placebo

    D. The evolution of Beck Hopelessness score which is a predictor of long-term suicide risk, under ketamine compared to placebo

    E. The early antidepressant efficacy of ketamine in depressed, uni- or bipolar patients

    F. The somatic and psychological tolerance of ketamine

    G. An overall improvement in the clinical condition of the patient by the practitioner

    H. Creation of a biological collection for future ancillary studies dedicated to genetic analysis (microRNA and mRNA).

    I. The efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS self-report questionnaire, in patients hospitalized for suicide risk.

    Participant Groups

    • Patients randomized to this group will be treated via Ketamine infusion. Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions

    • Patients randomized to this group will be treated via saline solution infusion. Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview
    * The patient is able to understand how the study is carried out and the tests performed
    * The patient is deemed capable of giving his/her informed consent
    * The patient has been correctly informed
    * The patient must have given his/her informed and signed consent.
    * The patient must be insured or beneficiary of a health insurance plan.
    * Presence of suicidal ideation according to the SSI score (score \> 3)
    * Negative pregnancy test for women of childbearing age

    Exclusion Criteria:

    * The patient is participating in another interventional study
    * Within the past three months, the patient has participated in another interventional study
    * The patient is in an exclusion period determined by a previous study
    * The patient is under judicial protection
    * The patient is an adult under guardianship
    * The patient refuses to sign the consent
    * The patient is not able to understand the informed consent
    * Pregnancy or breastfeeding
    * History of schizophrenia or other psychotic disorders
    * Presence of psychotic symptoms at initial interview
    * Schizoid or schizotypic personality disorder
    * Positive urine screening for illicit substances, excluding cannabis
    * Substance dependence in the preceding month (excluding nicotine or caffeine)
    * Concomitant treatment with electroconvulsive therapy
    * Unstable somatic pathology
    * Clinically significant anomalies found during clinical examination, biological test or ECG
    * Non-stabilized hypertension or hypertension \> 180/100
    * Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension

    Primary Outcomes

    • A suicidal ideation score measured using the BSS (Beck et al. 1979) in its hetero questionnaire form ≤ 3 at 24 hours after the second infusion of ketamine or placebo (yes/no). A threshold ≤ 3 separates the resolution of suicidal ideas from their persistence (Holi et al. 2005; DiazGranados et al. 2010).

    Secondary Outcomes
    • The occurrence of a suicide attempt or a completed suicide (yes/no) 6 weeks
    • Evaluation of the full spectrum of suicidality using the CSSRS Baseline (Day-2 to Day 0)
    • Evaluation of the full spectrum of suicidality using the CSSRS Day 1
    • Evaluation of the full spectrum of suicidality using the CSSRS Day 2
    • Evaluation of the full spectrum of suicidality using the CSSRS Day 3
    • Evaluation of the full spectrum of suicidality using the CSSRS Day 4
    • Evaluation of the full spectrum of suicidality using the CSSRS Week 2
    • Evaluation of the full spectrum of suicidality using the CSSRS Week 4
    • Evaluation of the full spectrum of suicidality using the CSSRS Week 6
    • The BSSI score Baseline (Day-2 to Day 0)
    • The BSSI score 40 min after end of 1st perfusion (Day 0)
    • The BSSI score 120 min after end of 1st perfusion (Day 0)
    • The BSSI score 4 hours after end of 1st perfusion (Day 0)
    • The BSSI score Day 1
    • The BSSI score Day 2
    • The BSSI score Day 4
    • The BSSI score Week 2
    • The BSSI score Week 4
    • The BSSI score Week 6
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Baseline (Day-2 to Day 0)
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model 40 min after end of 1st perfusion (Day 0)
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model 120 min after end of 1st perfusion (Day 0)
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model 4 hours after end of 1st perfusion (Day 0)
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Day 1
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Day 2
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Day 3
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Day 4
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Week 2
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Week 4
    • Evaluation of physical pain using a visual analog scale of 0 to 10 following a Lickert model Week 6
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Baseline (Day-2 to Day 0)
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model 40 min after end of 1st perfusion (Day 0)
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model 120 min after end of 1st perfusion (Day 0)
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model 4 hours after end of 1st perfusion (Day 0)
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Day 1
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Day 2
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Day 3
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Day 4
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Week 2
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Week 4
    • Evaluation of mental pain using a visual analog scale of 0 to 10 following a Lickert model Week 6
    • Evaluation of despair using the Beck Hopelessness Scale Baseline (Day-2 to Day 0)
    • Evaluation of despair using the Beck Hopelessness Scale Day 1
    • Evaluation of despair using the Beck Hopelessness Scale Day 2
    • Evaluation of despair using the Beck Hopelessness Scale Day 3
    • Evaluation of despair using the Beck Hopelessness Scale Day 4
    • Evaluation of despair using the Beck Hopelessness Scale Week 2
    • Evaluation of despair using the Beck Hopelessness Scale Week 4
    • Evaluation of despair using the Beck Hopelessness Scale Week 6
    • Evaluation of depression by the clinician (IDS-C30) Baseline (Day-2 to Day 0)
    • Evaluation of depression by the clinician (IDS-C30) 4 hours after end of 1st perfusion (Day 0)
    • Evaluation of depression by the clinician (IDS-C30) Day 1
    • Evaluation of depression by the clinician (IDS-C30) Day 2
    • Evaluation of depression by the clinician (IDS-C30) Day 3
    • Evaluation of depression by the clinician (IDS-C30) Day 4
    • Evaluation of depression by the clinician (IDS-C30) Week 2
    • Evaluation of depression by the clinician (IDS-C30) Week 4
    • Evaluation of depression by the clinician (IDS-C30) Week 6
    • Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up Baseline (Day-2 to Day 0)
    • Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up Day 1
    • Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up Day 2
    • Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up Day 3
    • Evaluation of somatic tolerance of ketamine using the Patient Rated Inventory of Side Effects (PRISE) throughout follow-up Day 4
    • Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) Baseline (Day-2 to Day 0)
    • Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) Day 1
    • Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) Day 2
    • Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) Day 3
    • Evaluation of psychic tolerance using the Young Mania Rating Scale (YMRS) Day 4
    • Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) Baseline (Day-2 to Day 0)
    • Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) Day 1
    • Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) Day 2
    • Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) Day 3
    • Evaluation of psychic tolerance using the Brief Psychiatric Rating Scale (BPRS) Day 4

    • Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted.

    • Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted.

    • Any abnormal hypertension, pulse oxymetry or cardiac frequency values observed during the study will be noted.

    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Baseline (Day-2 to Day 0)
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) 40 min after end of 1st perfusion (Day 0)
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) 120 min after end of 1st perfusion (Day 0)
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) 4 hours after end of 1st perfusion (Day 0)
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Day 1
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Day 2
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) 120 min after end of 2nd perfusion (Day 2)
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Day 3
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Day 4
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Week 2
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Week 4
    • Evaluation of the improvement of the patient's clinical condition using the Clinical Global Impression scale - Improvement (CGI-I) Week 6

    • A suicidal ideation score measured using the BSS (Beck et al. 1979) in its self report questionnaire form ≤ 3 at 24 hours after the second infusion of ketamine or placebo (yes/no). This scale is validated in French (de Man, Balkou \& Iglesias 1987); a threshold ≤ 3 separates the resolution of suicidal ideas from their persistence (Holi et al. 2005; DiazGranados et al. 2010)

    More Details

    NCT Number: NCT02299440
    Acronym: KETIS
    Other IDs: PHRC-N/2013/MA-01
    Study URL: https://clinicaltrials.gov/study/NCT02299440
    Last updated: Sep 29, 2023